Cough News and Research RSS Feed - Cough News and Research

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma. [More]
UB researchers successfully harness E. coli to generate new forms of antibiotics

UB researchers successfully harness E. coli to generate new forms of antibiotics

Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics -- including three that show promise in fighting drug-resistant bacteria. [More]
Pulmonary rehabilitation ‘should include sleep assessment’

Pulmonary rehabilitation ‘should include sleep assessment’

Researchers say that pulmonary rehabilitation programmes for patients with moderate to severe chronic obstructive pulmonary disease should include sleep assessment. [More]
DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

A special presentation at Digestive Disease Week 2015 featured GERD experts weighing in on their successful experience using Stretta therapy to treat challenging patient populations suffering from GERD. [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
Researchers make important breakthrough in identifying major drivers of excessive coughing

Researchers make important breakthrough in identifying major drivers of excessive coughing

Cough treatments could change dramatically after the herpes virus helped researchers discover that the respiratory tract links to two different parts of the nervous system. [More]
Two-drug combination improves lung function in some cystic fibrosis patients

Two-drug combination improves lung function in some cystic fibrosis patients

The combination of two drugs — an investigational drug used in conjunction with an already FDA-approved medication — improved lung function in patients with one form of cystic fibrosis, according to two new studies. [More]
Cough reflex sensitivity diminishes in participants exposed to e-cigarette, shows study

Cough reflex sensitivity diminishes in participants exposed to e-cigarette, shows study

With just one exposure to electronic-cigarette (e-cigarette) vapor, participants in a study of 30 healthy subjects demonstrated a diminishment of cough reflex sensitivity. [More]
No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference. [More]
IQWiG examines the added benefit of aclidinium bromide/formoterol drug combination in COPD patients

IQWiG examines the added benefit of aclidinium bromide/formoterol drug combination in COPD patients

The fixed-dose combination aclidinium bromide/formoterol has been approved since November 2014 for long-term treatment of adults with chronic obstructive pulmonary disease (COPD). [More]
Bronchitis can cause pneumonia, says Loyola physician

Bronchitis can cause pneumonia, says Loyola physician

When a cold has lasted too long or a cough is especially bothersome, it's important to see a medical professional. [More]
Long-term survivors of esophageal cancer still face continued risks, study finds

Long-term survivors of esophageal cancer still face continued risks, study finds

Patients with esophageal cancer who survive 5 years after undergoing surgery might breathe a sigh of relief and become complacent about continued monitoring. In fact, there is little published information on the outcome of patients with locally advanced esophageal cancer (LAEC) who survive beyond the 5-year mark. [More]
Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

Researchers at the University of Louisville have detailed a critical connection associated with a major environmental cause of silicosis and a form of lung cancer. Their study is reported in today's Nature Communications. [More]
Lung cancer surgery patients at higher risk of developing venous thromboembolism

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery. [More]
Advertisement
Advertisement